2014-2026 Global Ubiquitin Enzymes Industry Market Research Report, Segment by Player, Type, Application, Marketing Channel, and Region
SKU ID : Maia-15086611 | Publishing Date : 14-Jan-2020 | No. of pages : 139
The report covers market size status and forecast, value chain analysis, market segmentation of Top countries in
Major Region
s, such as North America, Europe, Asia-Pacific, Latin America and Middle East & Africa, by type, application and marketing channel. In addition, the report focuses on the driving factors, restraints, opportunities and PEST analysis of major regions.Major Companies Covered
Almac Discovery
Canaan Partners
BostonBiochem
Business Development Bank of Canada
5AM Ventures
Cell Signaling Technology
Cayman Chemicals
Boston University Technology Development Fund
Calculus Capital
Captor Therapeutics
C4 Therapeutics
Aileron Therapeutics
Cancer Research Technology
Amgen
AcelRx Pharmaceuticals
Aegera Therapeutics
Aju IB Investment
3SBio
Agilis Biotherapeutics
Boston Biochem
Apeiron Biologics
BPS Biosciences
Carmot Therapeutics
Aeneas Ventures
Abbiotec
Abcam
Celgene Corporation
Alexion Pharmaceuticals
Angelman Syndrome Foundation
Business Development Corporation (BDC) Capital
Major Types Covered
E1 AND E2 ENZYMES AS THERAPEUTIC TARGETS
E3 ENZYMES AS THERAPEUTIC TARGETS
DUB ENZYMES AS THERAPEUTIC TARGETS
ASSOCIATED DRUG CLASSES
Major Applications Covered
Cancer
Biological Engineering
Others
Top Countries Data Covered in This Report
United States
Canada
Germany
UK
France
Italy
Spain
Russia
Netherlands
Turkey
Switzerland
Sweden
Poland
Belgium
China
Japan
South Korea
Australia
India
Taiwan
Indonesia
Thailand
Philippines
Malaysia
Brazil
Mexico
Argentina
Columbia
Chile
Saudi Arabia
UAE
Egypt
Nigeria
South Africa
…
Years considered for this report:
Historical Years:
2014-2018Base Year:
2019Estimated Year:
2019Forecast Period:
2019-2026Frequently Asked Questions
- By product type
- By End User/Applications
- By Technology
- By Region